New treatment for kala azar, the most deadly parasitic disease after malaria

[Nairobi, Kenya -September 23, 2011]
Urgent support needed for governments to roll out treatments and control disease
East Africa is fighting the worst kala azar outbreak in a decade. Collaboration across the region through the Leishmaniasis East Africa Platform (LEAP) has resulted in the development of a new combination therapy (SSG&PM) which is cheaper and nearly halves the length of treatment from a 30 day course of injections to 17 days. East African endemic countries are taking the necessary regulatory measures to use it in their programmes, but experts warn that without international funding or interest in supporting governments in the roll out, too few patients will benefit.

New Child-Adapted Chagas Disease Treatment Approved for Registration

[Rio de Janeiro and Recife, Brazil, and Geneva, Switzerland – 2 December 2011]
Today, at the occasion of the 4th DNDi Partners’ Meeting in Rio de Janeiro, Brazil, Dr Carlos Gadelha, Secretary of Science, Technology and Strategic Products, Brazilian Ministry of Health, announced that Brazil’s National Health Surveillance Agency (ANVISA) granted registration of a new paediatric dosage form of benznidazole, developed through a partnership between the Pernambuco State Pharmaceutical Laboratory (LAFEPE) of Brazil and the Drugs for Neglected Diseases initiative (DNDi). Registration of this child-adapted formulation of benznidazole will be published on 12 December 2011.
[Español] [Português]

Children with HIV/AIDS Falling Through the Cracks of Treatment Scale-Up Efforts

[Geneva, Switzerland/New York, USA – 1 December 2011]
Less than one-quarter (23%) of children with HIV/AIDS who need treatment are getting it, according to a report released by the World Health Organization (WHO) on the occasion of World AIDS Day (1 December 2011). Although treatment coverage for adults has been steadily climbing and has now reached approximately half of those in need, coverage for children is lagging far behind, highlighted the Drugs for Neglected Diseases initiative (DNDi), a non-profit research and development organization that has recently launched a new paediatric HIV drug development programme.

Major Project Launched to Support India and Bangladesh’s National Control Programmes in Implementing New Treatments to Boost Kala-Azar Elimination Strategies

[Geneva, Switzerland, and New Delhi, India – 7 November 2011]
A comprehensive four-year project including over 10,000 patients in clinical and pharmacovigilance studies for diagnosis and treatment of visceral leishmaniasis (VL, also known as kala-azar) in India and Bangladesh was launched by an international consortium formed last month to support control and elimination strategies in both countries, where the concentration of disease burden is among the world’s highest.

DNDi Joins WIPO Open Innovation Platform But Calls for More Ambitious Provisions for Innovation and Access

[Geneva, Switzerland – October 26, 2011]
The Drugs for Neglected Diseases initiative (DNDi) welcomes the World Intellectual Property Organization (WIPO) initiative to create an open innovation platform – in the form of a searchable public database – to make intellectual property (IP), including compounds and regulatory data, for neglected disease innovation available for licensing. The initiative, called Re:Search, is being launched today in Geneva.

DNDi expands its activities to tackle urgent unmet needs for neglected patients in the field of helminth infections

[Geneva, Switzerland and Boston, USA – July 8, 2011]
Today at the Neglected Tropical Diseases Meeting of the International Society for Infectious Diseases (ISID-NTD) in Boston, the Drugs for Neglected Diseases initiative (DNDi) announced the first research and development project in its new helminth infection drug portfolio to address unmet needs of patients in Africa and Asia. The project will assess the potential of the drug flubendazole to treat a highly neglected subset of helminth infections, notably co-infection of two of the three filarial diseases: onchocerciasis (river blindness) and lymphatic filariasis (LF; elephantiasis), in co-infection with loiasis (African eyeworm or Loa loa). Existing treatments are inadequate and in some cases life-threatening. The project is supported by a grant from The Bill & Melinda Gates Foundation.
Listen to the podcast of Bernard Pécoul on DNDi‘s portfolio expansion to helminth infections

Innovative Partnership Advances Novel Drug Candidate to Combat Sleeping Sickness

[Washington, USA and Geneva, Switzerland – June 28, 2011]
PLoS Journal article highlights initial research success of a boron-based compound, ready to enter into clinical development, resulting from collaboration between two U.S. biotechs and DNDi
The Drugs for Neglected Diseases initiative (DNDi), Anacor Pharmaceuticals, and SCYNEXIS Inc. today announced the successful completion of pre-clinical studies for the first new oral drug candidate discovered specifically to combat human African trypanosomiasis (HAT), also known as sleeping sickness. An article released today in the open-access journal PLoS Neglected Tropical Diseases, reveals the initial successful results of pre-clinical studies of the new compound, which will soon advance to Phase I human clinical trials.
[Français] [Spañol] [Deutsch]

Sanofi and DNDi – Drugs for Neglected Diseases initiative – Sign an Innovative Agreement to Generate New Drugs for Neglected Tropical Diseases

[Paris, France and Geneva, Switzerland – May 30, 2011]
Sanofi (EURONEXT: SAN and NYSE:SNY) and Drugs for Neglected Diseases initiative (DNDi) announced today a three-year research collaboration agreement for the research of new treatments for nine neglected tropical diseases (NTDs), listed by the World Health Organization (WHO) for which new, adapted, and efficient tools are urgently needed to treat patients in endemic countries. This agreement is built upon a history of successful collaboration between Sanofi and DNDi.

Swiss Government firmly commits to fighting Neglected Diseases

[Geneva, Switzerland – April 28, 2011]
The Swiss Agency for Development and Cooperation (SDC) recently granted the Drugs for Neglected Diseases initiative (DNDi) a sum of four million Swiss Francs to be disbursed over three years. This grant reaffirms SDC’s increasing role as a major supporter of development and implementation of new treatments to fight neglected diseases, which affect millions in the poorest regions of the world.